Clinical stage biotech developing a powerful new class of cancer therapies exploiting chromosomal instability.
11 - 50
π° $60M Series A on 2023-03
July 16
π’ In-office - Manhattan
π΅ $160k - $210k / year
β° Full Time
π Senior
π Program Manager
π H1B Visa Sponsor